Novel Drug Delivery Systems for Releasing Growth Factors to the CNS: Focus on Alzheimer's and Parkinson's Diseases

被引：1
|
作者：
Herran, E. [1 ,2 ]
Igartua, M. [1 ,2 ]
Pedraz, J. L. [1 ,2 ]
Hernandez, R. M. [1 ,2 ]
机构：
[1] Univ Basque Country, UPV EHU, Sch Pharm, Lab Pharmaceut,NanoBioCel Grp, Vitoria 01006, Spain
[2] Biomed Res Networking Ctr Bioengn Biomat & Nanome, Vitoria, Spain
来源：
MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2014年 / 14卷 / 07期
关键词：
Alzheimer's disease; central nervous system; drug delivery systems; GDNF; Parkinson's disease; VEGF; CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; NEURAL STEM-CELLS; NEUROTROPHIC FACTOR; INTRANASAL DELIVERY; GENE-THERAPY; IN-VIVO; BEHAVIORAL RECOVERY; SECRETING CELLS; MOUSE MODEL;
D O I：
10.2174/1389557514666140622205058
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Alzheimer's disease (AD) and Parkinson's disease (PD) represent the most common neurodegenerative disorders and affect more than 35 million people. Due to the limited effectiveness of available treatments in halting the neurodegenerative process, new therapies, such therapies based on growth factors (GFs), have been investigated. Nevertheless, the efficacies of these new treatments depend not only on the application of neurotrophins but also on the approaches used to deliver these proteins such that they can reach the brain. This review summarises the most widely used drug delivery systems (DDSs) for releasing GFs as possible treatments for AD and PD.
引用
收藏
页码：557 / 566
页数：10
相关论文
共 50 条
  • [1] Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
    Cunha, S.
    Amaral, M. H.
    Sousa Lobo, J. M.
    Silva, A. C.
    CURRENT MEDICINAL CHEMISTRY, 2016, 23 (31) : 3618 - 3631
  • [2] Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases
    Nguyen-Thi, Phuong-Trang
    Ho, Thanh-Tam
    Nguyen, Thuy Trang
    Van Vo, Giau
    CURRENT DRUG DELIVERY, 2024, 21 (07) : 917 - 931
  • [3] Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases
    Hoelscher, Christian
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2014, 42 : 593 - 599
  • [4] Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer's and Parkinson's Diseases
    Jagaran, Keelan
    Singh, Moganavelli
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [5] Parkinson's and Alzheimer's diseases: Focus on mild cognitive impairment
    Korczyn, Amos D.
    PARKINSONISM & RELATED DISORDERS, 2016, 22 : S159 - S161
  • [6] Oral Health and Use of Novel Transbuccal Drug Delivery Systems in Patients with Alzheimer's and Parkinson's Disease: A Review
    Basilicata, Michele
    Grillo, Piergiorgio
    Tancredi, Alvise
    Di Fiore, Adolfo
    Bollero, Patrizio
    Stefani, Alessandro
    Schirinzi, Tommaso
    APPLIED SCIENCES-BASEL, 2023, 13 (08):
  • [7] Mesoporous silica nanoparticles: Their potential as drug delivery carriers and nanoscavengers in Alzheimer?s and Parkinson?s diseases
    Attia, Mohamed S.
    Yahya, Ahmed
    Monaem, Nada Abdel
    Sabry, Shereen A.
    SAUDI PHARMACEUTICAL JOURNAL, 2023, 31 (03) : 417 - 432
  • [8] Harmonization of drug approval guidelines in Alzheimer's and Parkinson's diseases
    Doody, RS
    Davidson, M
    Shoulson, I
    Whitehouse, P
    PROGRESS IN ALZHEIMER'S AND PARKINSON'S DISEASES, 1998, 49 : 861 - 865
  • [9] Risk in CNS drug discovery: focus on treatment of Alzheimer's Disease
    Pritchard, J. Fred
    BMC NEUROSCIENCE, 2008, 9 (Suppl 3) : S1
  • [10] Risk in CNS drug discovery: focus on treatment of Alzheimer's Disease
    J Fred Pritchard
    BMC Neuroscience, 9
12345